Literature DB >> 18625687

Acinetobacter baumannii: emergence of a successful pathogen.

Anton Y Peleg1, Harald Seifert, David L Paterson.   

Abstract

Acinetobacter baumannii has emerged as a highly troublesome pathogen for many institutions globally. As a consequence of its immense ability to acquire or upregulate antibiotic drug resistance determinants, it has justifiably been propelled to the forefront of scientific attention. Apart from its predilection for the seriously ill within intensive care units, A. baumannii has more recently caused a range of infectious syndromes in military personnel injured in the Iraq and Afghanistan conflicts. This review details the significant advances that have been made in our understanding of this remarkable organism over the last 10 years, including current taxonomy and species identification, issues with susceptibility testing, mechanisms of antibiotic resistance, global epidemiology, clinical impact of infection, host-pathogen interactions, and infection control and therapeutic considerations.

Entities:  

Mesh:

Year:  2008        PMID: 18625687      PMCID: PMC2493088          DOI: 10.1128/CMR.00058-07

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  601 in total

1.  Evaluation of the BD Phoenix automated identification and susceptibility testing system in clinical microbiology laboratory practice.

Authors:  E Stefaniuk; A Baraniak; M Gniadkowski; W Hryniewicz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-18       Impact factor: 3.267

2.  Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis.

Authors:  Gokhan Metan; Emine Alp; Bilgehan Aygen; Bulent Sumerkan
Journal:  Int J Antimicrob Agents       Date:  2006-11-28       Impact factor: 5.283

Review 3.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

4.  Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.

Authors:  David Landman; Simona Bratu; Maqsood Alam; John Quale
Journal:  J Antimicrob Chemother       Date:  2005-05-09       Impact factor: 5.790

5.  Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains.

Authors:  M J Rodríguez-Hernández; L Cuberos; C Pichardo; F J Caballero; I Moreno; M E Jiménez-Mejías; A García-Curiel; J Pachón
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

6.  Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.

Authors:  Daryl J Hoban; Samuel K Bouchillon; Michael J Dowzicky
Journal:  Diagn Microbiol Infect Dis       Date:  2007-04       Impact factor: 2.803

Review 7.  Sulbactam: a beta-lactamase inhibitor.

Authors:  J K Noguchi; M A Gill
Journal:  Clin Pharm       Date:  1988-01

8.  Spread of bla(CTX-M-type) and bla(PER-2) beta-lactamase genes in clinical isolates from Bolivian hospitals.

Authors:  Giuseppe Celenza; Cristina Pellegrini; Marisa Caccamo; Bernardetta Segatore; Gianfranco Amicosante; Mariagrazia Perilli
Journal:  J Antimicrob Chemother       Date:  2006-03-01       Impact factor: 5.790

9.  In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.

Authors:  Funda Timurkaynak; Fusun Can; Ozlem Kurt Azap; Müge Demirbilek; Hande Arslan; Sedef Ozbalikçi Karaman
Journal:  Int J Antimicrob Agents       Date:  2006-02-07       Impact factor: 5.283

10.  Toxicity after prolonged (more than four weeks) administration of intravenous colistin.

Authors:  Matthew E Falagas; Michael Rizos; Ioannis A Bliziotis; Kostas Rellos; Sofia K Kasiakou; Argyris Michalopoulos
Journal:  BMC Infect Dis       Date:  2005-01-10       Impact factor: 3.090

View more
  1043 in total

1.  The role of conserved surface hydrophobic residues in the carbapenemase activity of the class D β-lactamases.

Authors:  Marta Toth; Clyde A Smith; Nuno T Antunes; Nichole K Stewart; Lauren Maltz; Sergei B Vakulenko
Journal:  Acta Crystallogr D Struct Biol       Date:  2017-07-28       Impact factor: 7.652

2.  Co-production of AmpC and extended spectrum beta-lactamases in cephalosporin-resistant Acinetobacter baumannii in Egypt.

Authors:  Heba Shehta Said; Abdalbagi Basheer Benmahmod; Ramadan Hassan Ibrahim
Journal:  World J Microbiol Biotechnol       Date:  2018-12-03       Impact factor: 3.312

3.  Genomic comparison of multi-drug resistant invasive and colonizing Acinetobacter baumannii isolated from diverse human body sites reveals genomic plasticity.

Authors:  Jason W Sahl; J Kristie Johnson; Anthony D Harris; Adam M Phillippy; William W Hsiao; Kerri A Thom; David A Rasko
Journal:  BMC Genomics       Date:  2011-06-04       Impact factor: 3.969

4.  Genomewide analysis of divergence of antibiotic resistance determinants in closely related isolates of Acinetobacter baumannii.

Authors:  Mark D Adams; E Ricky Chan; Neil D Molyneaux; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

5.  In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging.

Authors:  Yucheng Wang; Olivia D Harrington; Ying Wang; Clinton K Murray; Michael R Hamblin; Tianhong Dai
Journal:  J Vis Exp       Date:  2017-04-28       Impact factor: 1.355

6.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

7.  Occurrence of an environmental Acinetobacter baumannii strain similar to a clinical isolate in paleosol from Croatia.

Authors:  Jasna Hrenovic; Goran Durn; Ivana Goic-Barisic; Ana Kovacic
Journal:  Appl Environ Microbiol       Date:  2014-02-28       Impact factor: 4.792

8.  Effect of Sodium Chloride on Surface-Associated Motility of Acinetobacter baumannii and the Role of AdeRS Two-Component System.

Authors:  P Malaka De Silva; Ayush Kumar
Journal:  J Membr Biol       Date:  2017-09-02       Impact factor: 1.843

Review 9.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

10.  Characterization and genome sequencing of phage Abp1, a new phiKMV-like virus infecting multidrug-resistant Acinetobacter baumannii.

Authors:  Guangtao Huang; Shuai Le; Yizhi Peng; Yan Zhao; Supeng Yin; Lin Zhang; Xinyue Yao; Yinling Tan; Ming Li; Fuquan Hu
Journal:  Curr Microbiol       Date:  2013-01-18       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.